Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

The federal government has allocated $1.15 billion to long-covid research without any new treatments yet brought to market. Patients and scientists say it’s time to push harder for breakthroughs.

Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.

The VDH and Scott are advocating for people to get their vaccinations before winter. Scott said he has received his COVID ...

The First Amendment's guarantees are not absolute. A person cannot “shout 'fire!' in a crowded theater,” and put the lives of ...